Number of patients with major morbidities
| . | No. (%) . | Median (range) . |
|---|---|---|
| Initial major morbidity . | 73 . | . |
| Death | 6 (8) | |
| No follow-up | 13 (18) | |
| Surviving patients (with follow-up) | 54 | |
| Duration of follow-up, y | 10 (1-47) | |
| No subsequent morbidities | 17 (31) | |
| Subsequent morbidities* | 37 (69) | |
| TIA/stroke | 21 | |
| Other neurologic abnormalities (hemiparesis, cognitive impairment) | 6 | |
| Acute kidney injury (without ESKD) | 2 | |
| ESKD (2 patients, kidney transplants) | 14 | |
| Cardiac injury (cardiomyopathy, congestive heart failure) | 2 | |
| Deaths attributed to subsequent morbidities (stroke, 5; ESKD, 3) | 8 | |
| Prophylaxis | 54 | |
| Patients | 39 (72) | |
| Prophylaxis began: | ||
| Before initial major morbidity | 7 | |
| At the time of initial major morbidity | 9 | |
| After initial major morbidity | 21 | |
| Not reported | 2 | |
| Recurrence of major morbidity after prophylaxis | 11 (28) |
| . | No. (%) . | Median (range) . |
|---|---|---|
| Initial major morbidity . | 73 . | . |
| Death | 6 (8) | |
| No follow-up | 13 (18) | |
| Surviving patients (with follow-up) | 54 | |
| Duration of follow-up, y | 10 (1-47) | |
| No subsequent morbidities | 17 (31) | |
| Subsequent morbidities* | 37 (69) | |
| TIA/stroke | 21 | |
| Other neurologic abnormalities (hemiparesis, cognitive impairment) | 6 | |
| Acute kidney injury (without ESKD) | 2 | |
| ESKD (2 patients, kidney transplants) | 14 | |
| Cardiac injury (cardiomyopathy, congestive heart failure) | 2 | |
| Deaths attributed to subsequent morbidities (stroke, 5; ESKD, 3) | 8 | |
| Prophylaxis | 54 | |
| Patients | 39 (72) | |
| Prophylaxis began: | ||
| Before initial major morbidity | 7 | |
| At the time of initial major morbidity | 9 | |
| After initial major morbidity | 21 | |
| Not reported | 2 | |
| Recurrence of major morbidity after prophylaxis | 11 (28) |
10 patients had multiple subsequent major morbidities.